Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging EvidenceHelgi Thor Hjartarson(Karolinska University Hospital), Thomas Sejersen(Karolinska University Hospital)Drug Design Development and TherapyJune 1, 202210.2147/dddt.s214174Cited by 57SaveCiteExport RISWatch citationsRelated PapersCancer Risk in Patients With Muscular Dystrophy and Myotonic Dystrophy|Neurology|2024|7